» Articles » PMID: 38389926

Herb-drug Interactions of Silybinin and Cilofexor in Beagle Dogs Based on Pharmacokinetics by UPLC-MS/MS

Overview
Journal Front Pharmacol
Date 2024 Feb 23
PMID 38389926
Authors
Affiliations
Soon will be listed here.
Abstract

A remarkably sensitive, accurate, and efficient ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) approach was developed as a facile and expeditious method for measuring cilofexor concentration in beagle dogs, the herb-drug interactions between silybinin and cilofexor was explored based on pharmacokinetics. The plasma sample protein of the beagles were rapidly sedimented with acetonitrile, and cilofexor and tropifexor (internal standard, ISTD) were separated by gradient elution using a 0.1% formic acid aqueous solution and acetonitrile as the mobile phase. The concentrations were detected using positive ion multiple reaction monitoring (MRM) mode. Mass transfer pairs were m/z 587.91→267.91 for cilofexor and m/z 604.08→228.03 for ISTD, respectively. A two-period self-controlled experimental design was adopted for the HDIs experiment. In the first period (Group A), six beagle dogs were orally administered cilofexor at a dose of 1 mg/kg. In the second period (Group B), silybinin (3 mg/kg) was orally administered to the six beagle dogs twice a day for seven consecutive days, after which cilofexor was orally administered. The cilofexor concentration in beagle dogs was determined, and HDIs were evaluated based on their pharmacokinetics. The accuracy and precision of cilofexor were both less than 15%, and the recoveries, matrix effects, and stability met the relevant requirements. The C of cilofexor in group B was 49.62% higher than that in group A, whereas the AUC and AUC of cilofexor in group B were 47.85% and 48.52% higher, respectively, than those in group A. Meanwhile, the t extended from 7.84 h to 9.45 h, CL and Vz decreased in Group B. A novel UPLC-MS/MS approach was successfully applied for the measurement of cilofexor in beagle dog plasma. Silybinin can alter the pharmacokinetics of cilofexor in beagle dogs, thereby increasing plasma exposure to cilofexor.

References
1.
Bi Y, Kang Y, Woshur G, Ding H, Wang S, Qiu X . Effect of Chaihu Shugan Pills on the Pharmacokinetics of Duloxetine and its Metabolite 4-Hydroxyduloxetine in Beagle Dogs: A Herb-Drug Interaction Study. Evid Based Complement Alternat Med. 2022; 2022:2350560. PMC: 9402319. DOI: 10.1155/2022/2350560. View

2.
Raza S, Rajak S, Upadhyay A, Tewari A, Sinha R . Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed). 2020; 26(2):206-237. PMC: 7116261. DOI: 10.2741/4892. View

3.
Weber E, Younis I, Nelson C, Ding D, Qin A, Xiao D . Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist. J Clin Pharmacol. 2023; 63(5):560-568. DOI: 10.1002/jcph.2206. View

4.
Zhou X, Fu L, Wang P, Yang L, Zhu X, Li C . Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs: Insights from experimental studies, mechanistic actions to clinical applications. Biomed Pharmacother. 2021; 138:111445. DOI: 10.1016/j.biopha.2021.111445. View

5.
Liu Y, Xu W, Zhai T, You J, Chen Y . Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B. 2019; 9(4):745-757. PMC: 6664044. DOI: 10.1016/j.apsb.2019.02.006. View